Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
PRDM16
REST API REST API
Homo sapiens
PRDM16 is differentially expressed in 165 experiments: 95 organism parts: skeletal muscle, pituitary gland, ... (93 more);, 97 disease states: normal, healthy, ... (95 more);, 40 cell types 201 cell lines 18 compound treatments and 55 other conditions.
Synonyms MGC166915, KIAA1675, PFM13, MEL1
Orthologs PRDM16 (Gallus gallus)   Prdm16 (Mus musculus)   prdm16 (Danio rerio)   PRDM16 (Bos taurus)   CG10348 (Drosophila melanogaster)   ham (Drosophila melanogaster)   LOC100485690 (Xenopus laevis)   PRDM16 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term transcriptional repressor complex, DNA binding, negative regulation of transcription, DNA-dependent, protein binding, intracellular, neurogenesis, metal ion binding, nucleic acid binding, negative regulation of transforming growth factor beta receptor signaling pathway, sequence-specific DNA binding, transcription coactivator activity, nucleus, somatic stem cell maintenance, SMAD binding, negative regulation of transcription from RNA polymerase II promoter, positive regulation of transcription, DNA-dependent, zinc ion binding, negative regulation of granulocyte differentiation, regulation of cellular respiration, palate development, brown fat cell differentiation, tongue development, white fat cell differentiation
InterPro Term Znf_C2H2-like, Znf_BED_prd, Znf_C2H2, SET_dom
UniProt Accession D6RDW0, D6RFY3, Q9HAZ2, D3YTA5, F8WEV3
Search EB-eye ENSG00000142611
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MTAB-24, ... (18 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-2450, ... (24 experiments)

Factor Value U/D Experiments
DU145
2
E-GEOD-17482, E-GEOD-20089
SNU1
2
E-MTAB-37, E-GEOD-15460
EA.hy926
1
E-GEOD-2450
HCC38
1
E-MTAB-62
A101D
1
1
E-MTAB-37
NCIH748
1
E-MTAB-37
195 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, ... (26 experiments)

Factor Value U/D Experiments
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
plasma cell
1
E-MEXP-2360
CD3- CD56bright CD62L+ NK cell
1
1
E-GEOD-21774
partially reprogrammed human induced pluripotent stem cell
1
E-GEOD-18147
2
1
E-TABM-130
osteoblast
1
E-MEXP-1216
34 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1922, E-GEOD-8581, E-GEOD-15960, E-GEOD-1869, ... (31 experiments)

Factor Value U/D Experiments
prostate carcinoma
2
E-GEOD-7307, E-MTAB-62
plasma-cell leukemia
1
E-MTAB-62
superficial transitional cell carcinoma without surrounding carcinoma in situ lesion
1
E-GEOD-3167
undifferentiated sarcoma
1
E-MEXP-1922
non-ischemic cardiomyopathy
1
E-GEOD-1869
monophasic synovial sarcoma
1
E-MTAB-62
91 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-3284, E-GEOD-15205, E-GEOD-5741, E-GEOD-2292, ... (12 experiments)

Factor Value U/D Experiments
none
2
E-GEOD-1615, E-GEOD-5741
no estradiol
1
E-GEOD-20081
hydrogen peroxide
1
E-GEOD-5339
unknown
1
E-GEOD-7307
valproic acid
1
E-GEOD-1615
17beta-estradiol
4
1
E-GEOD-2292
12 more value(s).


Age at diagnosis

studied in E-GEOD-21653

Factor Value U/D Experiments
80
2
1
E-GEOD-21653


Agent
studied in E-GEOD-19519

Biosource provider
studied in E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363 ... (5 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-3140, E-MEXP-2359, E-GEOD-4667

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-GEOD-21138

Environmental stress
studied in E-GEOD-1643

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Genetic modification
studied in E-GEOD-8023, E-GEOD-7578, E-MTAB-108, E-MEXP-563

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-17476, E-TABM-321

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-127, E-GEOD-9764, E-MEXP-1103, E-GEOD-20505

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-974, E-TABM-666, E-GEOD-19519, ... (19 experiments)

Infection
studied in E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Organism
studied in E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-GEOD-2004

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-19246, E-GEOD-1343

RNAi
studied in E-MEXP-101, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-18995

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Treatment
studied in E-GEOD-19246

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271

Processing time: 0.398 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM